Last updated:
ID:
592266
Start date:
30 April 2025
Project status:
Current
Principal investigator:
Dr Yang Liu
Lead institution:
Peking University, China

What are the key genetic, proteomic, metabonomic, environmental, clinical, and lifestyle factors contributing to the onset and progression of valvular disease?
How can integrating multifaceted data improve risk factor identification compared to traditional approaches?
What are the predictive capabilities of AI models in identifying high-risk individuals for valvular disease?

To develop an integrated framework combining genetic, proteomic, metabonomic, clinical, environmental, and behavioral data to analyze their collective impact on valvular disease.
To identify and validate novel risk factors associated with valvular disease using large-scale datasets.
To apply machine learning and statistical modeling to predict disease risk and provide personalized insights.
To propose actionable prevention strategies based on modifiable risk factors.

Valvular disease significantly contributes to cardiovascular morbidity and mortality, yet its risk factors remain poorly understood due to the complex, multifactorial nature of the disease. Traditional studies often examine isolated variables, missing the interactions between genetic predisposition, environmental exposures, and lifestyle factors. This research aims to fill this gap by integrating multifaceted data, providing a more comprehensive assessment of disease risk.

We will also request access to participants’ home location histories (latitude and longitude) to assess long-term environmental exposures, such as air pollution and geographical variables, in relation to health outcomes. By integrating these data, we aim to enhance risk prediction models and identify novel environmental risk factors.

The use of advanced computational tools like AI and machine learning will allow for the analysis of high-dimensional data and uncover patterns that are not detectable with traditional methods, enabling more accurate predictions of disease risk and improved patient outcomes.